CPA
TRVI icon

Capital Performance Advisors’s Trevi Therapeutics TRVI Stock Holding History

Capital Performance Advisors’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-134
Closed -$448 – 2492
2024
Q3 		$448 Buy
+134
New +$398 ﹤0.01% 2300

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Capital Performance Advisors's TRVI Position: Q4 2024 in Review

Capital Performance Advisors sold out of Trevi Therapeutics (TRVI) in Q4 2024, closing a stake of 134 shares — an estimated $448 sold.

Capital Performance Advisors first reported a position in TRVI in Q3 2024 and held it in 1 quarter. The position peaked at $448 in Q3 2024. 110 funds tracked by Wall St. Rank hold TRVI as of Q4 2024.

  • Capital Performance Advisors reported no remaining Trevi Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Capital Performance Advisors sold 134 Trevi Therapeutics shares in Q4 2024, an estimated $448.
  • Capital Performance Advisors first reported a position in Trevi Therapeutics in Q3 2024 and held it in 1 quarter.
  • Capital Performance Advisors's Trevi Therapeutics position peaked at $448 in Q3 2024.
  • 110 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.